a ntibody -b ased t herapeutics for t reating a lzheimer ’ s and p arkinson ’ s d iseases taylor...

7
ANTIBODY-BASED THERAPEUTICS FOR TREATING ALZHEIMER’S AND PARKINSON’S DISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012 Arizona/NASA Space Grant Symposium University of Arizona April 21, 2012

Upload: franklin-hubbard

Post on 18-Jan-2018

222 views

Category:

Documents


0 download

DESCRIPTION

R ESEARCH O BJECTIVES Process of protein misfolding and accumulation causes disease β-amyloid and α-synuclein are two biomarkers (proteins) linked to AD and PD Oligomeric forms of β-amyloid and α-synuclein are the key toxic species 3 Identify antibodies to detect β-amyloid and α-synuclein Can be used for therapeutics and diagnostics

TRANSCRIPT

Page 1: A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012

ANTIBODY-BASED THERAPEUTICS

FOR TREATING ALZHEIMER’S AND PARKINSON’S DISEASES

Taylor Brownlee

Dr. Michael SierksChemical Engineering

2012 Arizona/NASA Space Grant SymposiumUniversity of Arizona

April 21, 2012

Page 2: A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012

WHAT CAUSES ALZHEIMER’S AND PARKINSON’S DISEASES? Alzheimer’s disease (AD) and Parkinson’s disease (PD)

are devastating neurodegenerative diseases

Plaques and tangles (AD) or Lewy bodies (PD) Accumulate in different areas of the brain Block nerve cell

communication and cause cell death

Presence of plaques and tangles or Lewybodies is not a definitivediagnosis for AD or PD

2

http://www.ahaf.org/alzheimers/

Page 3: A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012

RESEARCH OBJECTIVES Process of protein misfolding and accumulation

causes disease

β-amyloid and α-synuclein are two biomarkers (proteins) linked to AD and PD

Oligomeric forms of β-amyloid and α-synuclein are the key toxic species

3

Identify antibodies to detectβ-amyloid and α-synuclein

Can be used for therapeutics and diagnostics

Page 4: A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012

SANDWICH ELISA 4

Page 5: A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012

5

1E-05 1E-04 1E-03 1E-020.26

0.27

0.28

0.29

0.30

Phage (mg/mL)1E-061E-07

PD Biomarker (mg/mL)

PD B

iom

arke

r Sig

nal

RESULTS FOR PD ANTIBODY

Page 6: A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012

CONCLUSIONS Process of protein misfolding and accumulation

causes Alzheimer’s and Parkinson’s diseases

Antibodies detect toxic biomarker species that cause AD and PD

Sandwich ELISA detects the biomarker concentration

1E-07 M13 bacteriophage concentration yielded the largest biomarker signal

Further study must be done to perfect ELISA protocol

6

Page 7: A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012

THANK YOU!

QUESTIONS?